Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)-Reference-Cited by-同舟云学术

Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)

Published:1987 Issue:3 Volume:11 Page:281-290
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Geldof A. A.,De Voogt H. J.,Rao B. R.

Publisher

Wiley

Subject

Urology,Oncology

Reference23 articles.

1. Inhibitory Effects of Long Term Treatment with a Luteinizing Hormone-Releasing Hormone Agonist on the Pituitary-Gonadal Axis in Male and Female Rats

2. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men**Supported in part by the National Cancer Institute of Canada; Hoechst AG, Frankfurt, West Germany.

3. Inhibition of Pituitary-Testicular Function with [D-Trp6] Luteinizing Hormone-Releasing Hormone in Rhesus Monkeys*

4. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.

5. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consideration of the use of 17?-N,N-diethylcarbamoyl-4-methyl-4-aza-5-?-androstan-3-one (4MA), a 5?-reductase inhibitor, in prostate cancer therapy;Journal of Cancer Research and Clinical Oncology;1992-01

2. Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327;The Prostate;1991

3. Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer;The Prostate;1988